Management of ascites in cirrhosis - PowerPoint PPT Presentation

About This Presentation
Title:

Management of ascites in cirrhosis

Description:

Management of ascites in cirrhosis BSG 2006 Definition Pathogenesis Diagnosis- asctitic fluid analysis Treatment- salt restriction/diuretic Therapeutic paracentesis ... – PowerPoint PPT presentation

Number of Views:373
Avg rating:3.0/5.0
Slides: 39
Provided by: Deb8152
Category:

less

Transcript and Presenter's Notes

Title: Management of ascites in cirrhosis


1
Management of ascites in cirrhosis
  • BSG 2006

2
  • Definition
  • Pathogenesis
  • Diagnosis- asctitic fluid analysis
  • Treatment- salt restriction/diuretic
  • Therapeutic paracentesis
  • TIPSS
  • SBP

3
Setting the scene
  • Occurs in 50 of patients over 10yrs
  • Associated with 50 mortality over two yrs
  • Indicates the need to consider liver
    transplantation
  • Mortality from cirrhosis is 12.7 per 100,000
    population
  • Approx 4 of population have abnormal LFT, 10-20
    of those develop cirrhosis over 10-20yrs

4
  • Uncomplicated ascites- not infected and not
    associated with HRS
  • Refractory ascites- cannot be mobilised or early
    recurrence of which ( that is after therapeutic
    paracentesis) cannot be prevented by medical
    treatment
  • Diuretic resistant ascites- refractory to dietary
    salt restriction and intensive diuretic treatment
    ( spironolactone 400mg and frusemide 160mg per
    day and salt restricted diet of less than
    90mmol/day ( 5.2g/day)
  • Diuretic intolerant ascites- refractory to
    therapy due to the development of diuretic
    induced complications

5
Grading of ascites
  • Grade I Only detectable by US
  • Grade II Moderate symmetrical distension of the
    abdomen
  • Grade III Marked abdominal distension

6
Pathogensis
  • Portal hypertension
  • Sodium and water retention

7
Role of portal hypertension
  • PH increases the hydrostatic pressure with the
    hepatic sinusoid and favours transudation of
    fluid into the peritoneal cavity
  • PH occurs as a consequence of structural changes
    within the liver in cirrhosis and increased
    splanchnic blood flow

8
  • Progressive collagen deposition and nodule
    formation alter vascular architecture and
    increases the resistance to portal flow
  • Collagen is formed within the space of Disse and
    sinusoids become less distensible

9
  • Increased splanchnic flow because of vasodilation
    due to release of NO

10
(No Transcript)
11
  • Increased resistance in the hepatic sinusoid
  • Portal hypertension
  • Congestion of capillary in intestine
  • Endotoxaemia
  • NO release
  • Arterial vasodilation in both systemic and
    splanchnic circulation- systemic ( tachycardia
    increased stroke volume) and splanchnic (
    increased portal flow- and more rise in portal
    pressure)
  • Decrease in effective circulatory volume
  • Activation of RAS system and sympathetic system-
    ( aldosterone increase promoting Na retention and
    secondary fluid retention to restore blood
    volume)
  • Renal vasoconstriction to increase glomerular
    pressure- ultimately attempts at homeostasis
    fails- GFR starts to fall

12
  • Sinusoidal endothelial cells form and extremely
    porous membrane almost completely permeable to
    macromolecule
  • Old theory that low albumin is the cause of
    ascites is false as there is no oncotic gradient
    ( it works for peripheral oedema but not for
    ascites)
  • Portal hypertension is critical to development to
    ascites and develops when wedged hepatic portal
    venous pressure is more than 12mm
  • TIPSS relieves ascites by reducing portal
    hypertension though low albumin and cirrhotic
    liver persists

13
  • Presinusoidal portal hypertension does not
    produce ascites ( portal vein thrombosis)
  • Post sinusoidal portal hypertension does produce
    back pressure and cause similar haemodynamic
    changes and causes ascites ( hepatic vein
    thrombosis)

14
  1. Sinusoidal portal hypertension, in the presence
    of severe hepatic decompensation
  2. Leads to splanchnic and systemic
    vasodilatation-role of NO
  3. Decreased effective arterial blood volume
  4. Activation of systemic vasoactive factors, such
    as the renin-angiotensin system, the sympathetic
    nervous system, and vasopressin aimed at
    restoring arterial filling pressure.
  5. Renal vasoconstriction increases concomitantly
    (leukotrienes and endothelins), counterbalanced
    by the intrarenal hyperproduction of vasodilating
    prostaglandins. When this balance is lost renal
    hemodynamics worsens, and hepatorenal syndrome
    develops

15
  • Cirrhosis 75
  • Malignancy 10
  • Heart failure 3
  • TB 2
  • Pancreatitis 1

16
  • Blood tests- FBC/UE/LFT/INR
  • Ultrasound- liver/spleen/portal vein/LN
  • Ascitic fluid analysis

17
Abdominal paracentesis
  • 15cm lateral to umbilicus
  • Avoid enlarged spleen and liver
  • Avoid sp and inf epigastric arteries
  • No data to support use of FFP
  • Most clinicians would give pooled platelets if
    lt40
  • Complication
  • Haematomalt1
  • Bowel perforation/haemoperitoneum lt0.1
  • 10-20ml of fluid in a syringe with blue/green
    needle

18
  • Blood culture bottle- culture
  • EDTA tube- cell type
  • Yellow top tube- albumin/amylase
  • Yellow top tube- blood ( for serum albumin)

19
Ascitic fluid neutrophil count and culture
  • SBP is present in 15 patients admitted to
    hospital
  • Ascitic neutrophil count of gt250cells/mm3 is
    diagnostic of SBP in absence of perforated viscus
    or inflammation of intraabdominal organs
  • RBC count is usually lt1000cells/mm3
  • In 2 of cirrhotic bloody ascites gt50,000
  • In bloody ascites 50 no cause and 30 HCC

20
  • The prevalence of occult ascitic fluid infection
    in asymptomatic outpatients undergoing large
    volume paracentesis for resistant ascites is low
  • As a result, the routine culture of fluid during
    paracentesis in such patients is probably not
    warranted.
  • Obtain a cell count and differential on all
    samples of ascitic fluid while obtaining cultures
    only in symptomatic patients.

21
  • Culture in sterile container will identify onlY
    40 of cases of SBP
  • Whereas culture in blood culture bottle will
    identify 72-90
  • Gram stain and AFFB stain inappropriate
  • Fluid culture for mycobacteria 50 sensitivity

22
  • Cytology is 60-90 accurate in malignant ascites
    if several hundred ml of fluid is sent and
    concentration technique is used
  • But it is not investigation of choice in HCC

23
  • Previously transudate if gt25g/L and exudate if
    gt25g/L of protein
  • Up to 30 of cirrhosis will be exudate if we use
    protein to categorize
  • SAAG is far superior with 97 accuracy
  • Eg Serum albumin 26 and ascitic albumin 11- so
    SAAG is 15- so high SAAG- previously called
    transudate

SAAGgt11g/L Cirrhosis Cardiac failure Nephrotic
syndrome
SAAGlt11g/L Malignancy Pancreatitis Tuberculosis
24
  • Amylase in pancreatic ascites
  • Triglyceride in chylous ascites
  • Bilirubin in post op ascites

25
Treatment-bed rest
  • No clinical data to back up the finding that
    upright position is asscociated with reduced GFR
    and reduced Na excretion and reduced diuretic
    efficacy
  • Bed rest promote muscle atrophy and other
    complications and extends hospital stay
  • So bed rest not recommended

26
Treatment- salt restriction
  • Typical UK diet has 150mmol/day- 15 added salt
    and 70 is manufactured salt
  • Suggestion is no added salt diet and avoidance of
    prepared food
  • So that patient gets 90mmol/day ( 5.2gm)
  • Lowers diuretic requirement, faster resolution of
    ascites and shorter hospital stay
  • Avoid high salt content of fluid and medicine
    except in HRS

27
Treatment- water restriction
  • No role in uncomplicated ascites
  • Most hepatologists restrict fluid in ascites
    associated with hyponatraemia- but is illogical
  • The downside is water restriction causes increase
    in the central effective hypovolaemia- more ADH-
    more water retension and further dilutional
    hyponatraemia
  • So hepatologist including the authors of the BSG
    guidelines suggest further plasma expansion to
    inhibit ADH secretion
  • Data emerging supporting use of specific
    vasopressin 2 receptor antagonists
  • To be effective the intake should be less than
    urine output rather than arbitrary 1.5L/day
  • If the serum sodium concentration does not
    increase within the first 24 to 48 hours, the
    degree of fluid restriction has been
    insufficient.

28
Treatment- diuretic
  • Spironolactone is drug of choice
  • Aldosterone antagonist acting in distal tubule to
    increase natriuresis and conserve potassium
  • Initial dose 100mg and increasing up to 400mg
  • Lag of 3-5days
  • Better natriuresis and diuresis than a loop
    diuretic
  • Antiandrogenic effect- gynaecomazia- tamoxifen
    20mg bd
  • Hyperkalaemia frequently limits the use

29
Treatment- diuretic
  • Frusemide has low efficacy in cirrhosis
  • Use only if 400mg of spironolactone fails to
    achieve weight loss
  • Start at 40mg a day and increasing by 40mg every
    3rd day to max of 160mg
  • Watch out for metabolic alkalosis and electrolyte
    disturbance

30
Treatment- diuretic
  • Stepped care approach
  • Till oedema is present no need to slow down the
    daily weight loss
  • Once oedema is resolved daily weight loss
    should be less than 0.5kg per day
  • Over diuresis is associated with intravascular
    volume depletion, leading to renal impairment,
    hepatic encephalopathy and hyponatraemia
  • 10 will have refractory ascites
  • Dietary history to exclude salt ingestion- 24hr
    urinary Na excretion should be less than
    recommended intake
  • Drug history - NSAID

31
Problem with hyponatraemia
Na 126-135 and normal creatinine Continue diuretic Do not water restrict
Na 121-125 and normal creatinine Continue/? discontinue
Na 121-125 and high Creatinine Stop diuretic and give volume expansion
Na lt120 Stop diuretic
32
Controversy regarding normal saline
  • Give only if renal function is worsening
    creatinine gt150 or 120 and rising
  • Gelofusion/Haemaccel/ 4.5 albumin all have
    153mmol of Na per L
  • This will worsen salt retention but better to
    have ascites than to develop HRS

33
Therapeutic paracentesis
  • Total paracentesis is associated with significant
    haemodynamic changes
  • Large volume paracentesis causes marked reduction
    of IAP and IVC pressure- decrease in right heart
    pressure and
  • This changes are maximal at 3hrs

34
  • International ascites club recommend if lt5L is
    removed synthetic plasma expander can be used and
    as good as albumin ( some hepatologist suggests
    no albumin/plasma expander if lt5L)
  • Compared to albumin, artificial plasma expander
    cause more activation of RAS , causes more
    hyponatraemia and results in longer hospital stay
  • 20 albumin should be infused after paracentesis
    of gt5L at dose of 8g/L of ascites drained ( 100ml
    of 20 albumin 20gm, so 3L of ascites fluid
    removal needs 3x824 gm of albumin replacement
    125ml but we tend to round it to 100ml)
  • So if gt10L remember to give an extra 100ml of
    albumin
  • 25 albumin can be given if the patient is
    hypervolemic while 5 percent albumin can be given
    if dehydration is suspected.

35
  • Use Z technique- puncture site on the skin does
    not overlie the puncture site on peritoneum
  • Left flank is preferrable to right flank
  • After drain is out patient lie on opposite site
  • Colostomy bag if continuous leakage ( some use
    purse string suture)
  • As rapidly as possible- should not be left
    overnight
  • No upper limit of 8 litres or maximum time of 6
    hours has been mentioned in the guidelines

36
  • 10 of patients will have refractory ascites and
    will need paracentesis
  • Following paracentesis ascites will recur in 93
    if diuretic is not reinstituted and only 18 if
    treated with spironolactone
  • Reintroduction of diuretics after 1-2 days does
    not appear to increase the risk of post
    paracentesis circulatory dysfunction

37
TIPSS
  • Highly effective treatment
  • Complete resolution in 75 of cases
  • No effect on survival in one study and reduced on
    others- compared with therapeutic paracentesis
  • HE occurs in 25 of patients , more if gt60yrs
  • May precipitate heart failure as increase cardiac
    preload
  • TIPSS should be considered for patients who
    require frequent paracentesis ( gt3 a month)
  • It also shown to resolve hepatic hydrothorax in
    60-70
  • MELD was originally developed to predict survival
    after TIPSS insertion

38
Prognosis
  • Mortality of 50 within 2yr of diagnosis
  • Once refractory to medical therapy 50 die within
    6 months
  • Time for referral to transplant centre as
    paracentesis and TIPSS does not improve long term
    survival except improving quality of life
Write a Comment
User Comments (0)
About PowerShow.com